Sentry Investment Management LLC trimmed its holdings in Edwards Lifesciences Corp (NYSE:EW) by 8.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 12,126 shares of the medical research company’s stock after selling 1,077 shares during the quarter. Sentry Investment Management LLC’s holdings in Edwards Lifesciences were worth $2,320,000 at the end of the most recent reporting period.
A number of other large investors have also bought and sold shares of EW. Executive Wealth Management LLC acquired a new position in shares of Edwards Lifesciences in the fourth quarter worth about $25,000. FTB Advisors Inc. acquired a new position in shares of Edwards Lifesciences in the first quarter worth about $25,000. Sontag Advisory LLC acquired a new position in shares of Edwards Lifesciences in the fourth quarter worth about $26,000. Lindbrook Capital LLC acquired a new position in shares of Edwards Lifesciences in the fourth quarter worth about $27,000. Finally, Capital Financial Planning LLC acquired a new position in shares of Edwards Lifesciences in the fourth quarter worth about $28,000. 84.43% of the stock is currently owned by institutional investors.
In related news, VP Donald E. Bobo, Jr. sold 300 shares of the company’s stock in a transaction dated Wednesday, May 8th. The shares were sold at an average price of $178.54, for a total transaction of $53,562.00. Following the completion of the sale, the vice president now owns 19,415 shares of the company’s stock, valued at approximately $3,466,354.10. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP Catherine M. Szyman sold 1,474 shares of the company’s stock in a transaction dated Thursday, February 21st. The shares were sold at an average price of $176.34, for a total transaction of $259,925.16. Following the sale, the vice president now directly owns 15,905 shares of the company’s stock, valued at approximately $2,804,687.70. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 153,780 shares of company stock valued at $27,129,483. 1.63% of the stock is owned by corporate insiders.
EW has been the subject of a number of analyst reports. Raymond James decreased their price objective on shares of Edwards Lifesciences from $210.00 to $200.00 and set an “outperform” rating for the company in a research report on Wednesday, April 24th. Barclays upped their price target on shares of Edwards Lifesciences from $150.00 to $160.00 and gave the stock an “underweight” rating in a research report on Monday, March 25th. Morgan Stanley upped their price target on shares of Edwards Lifesciences from $180.00 to $197.00 and gave the stock an “overweight” rating in a research report on Monday, March 18th. UBS Group upped their price target on shares of Edwards Lifesciences from $175.00 to $180.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 12th. Finally, Canaccord Genuity restated a “buy” rating and set a $215.00 price target (up previously from $190.00) on shares of Edwards Lifesciences in a research report on Monday, March 18th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and thirteen have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $187.00.
NYSE EW traded up $0.93 during trading hours on Tuesday, hitting $173.71. 18,094 shares of the company’s stock traded hands, compared to its average volume of 1,285,679. Edwards Lifesciences Corp has a 52-week low of $134.38 and a 52-week high of $197.86. The stock has a market cap of $36.10 billion, a PE ratio of 36.87, a P/E/G ratio of 2.22 and a beta of 0.85. The company has a current ratio of 3.66, a quick ratio of 2.69 and a debt-to-equity ratio of 0.17.
Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Tuesday, April 23rd. The medical research company reported $1.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.09. Edwards Lifesciences had a net margin of 20.03% and a return on equity of 31.16%. The company had revenue of $993.00 million during the quarter, compared to analysts’ expectations of $989.87 million. During the same quarter in the prior year, the company earned $1.22 EPS. Edwards Lifesciences’s revenue was up 11.0% compared to the same quarter last year. On average, sell-side analysts forecast that Edwards Lifesciences Corp will post 5.28 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Sentry Investment Management LLC Sells 1,077 Shares of Edwards Lifesciences Corp (EW)” was first reported by Highlight Press and is the sole property of of Highlight Press. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at https://highlightpress.com/2019/05/21/sentry-investment-management-llc-sells-1077-shares-of-edwards-lifesciences-corp-ew.html.
Edwards Lifesciences Company Profile
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.
Read More: What Are Treasury Bonds?
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.